🏛️ Verified NIH Record • Updated 2024-12-02
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy (NCT02573636)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
🩺 Plain-English Summary (8th-Grade Level)
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
Who can join: Review the eligibility criteria below.
Location: CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi — Chicoutimi, Quebec
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi — Chicoutimi, Quebec
- CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne — Greenfield Park, Quebec
- CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval — Laval, Quebec
- CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont — Montreal, Quebec
- Jewish General Hospital, McGill University — Montreal, Quebec
- MUHC - Cedars Cancer Center — Montreal, Quebec
- CHU - L'Hôtel-Dieu de Québec — Québec, Quebec
- CIUSSS de l'Estrie - Hôpital Fleurimont — Sherbrooke, Quebec
- CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières — Trois-Rivières, Quebec
📞 Contact the Study Coordinator
Phone: (514) 340-8222
Email: yanqi.feng.ccomtl@ssss.gouv.qc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.